Soleno Therapeutics Past Earnings Performance
Past criteria checks 0/6
Soleno Therapeutics's earnings have been declining at an average annual rate of -19.4%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 109.1% per year.
Key information
-19.4%
Earnings growth rate
34.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 109.1% |
| Return on equity | -115.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Soleno Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 0 | -23 | 10 | 16 |
| 31 Mar 22 | 0 | -28 | 10 | 18 |
| 31 Dec 21 | 0 | -31 | 11 | 21 |
| 30 Sep 21 | 0 | -31 | 10 | 23 |
| 30 Jun 21 | 0 | -31 | 10 | 23 |
| 31 Mar 21 | 0 | -28 | 10 | 24 |
| 31 Dec 20 | 0 | -25 | 9 | 23 |
| 30 Sep 20 | 0 | -36 | 8 | 23 |
| 30 Jun 20 | 0 | -27 | 7 | 23 |
| 31 Mar 20 | 0 | -30 | 7 | 20 |
| 31 Dec 19 | 0 | -31 | 7 | 16 |
| 30 Sep 19 | 0 | -16 | 7 | 13 |
| 30 Jun 19 | 0 | -19 | 7 | 11 |
| 31 Mar 19 | 0 | -16 | 7 | 9 |
| 31 Dec 18 | 0 | -12 | 7 | 7 |
| 30 Sep 18 | 0 | -16 | 7 | 6 |
| 30 Jun 18 | 0 | -17 | 7 | 5 |
| 31 Mar 18 | 0 | -13 | 7 | 4 |
| 31 Dec 17 | 0 | -12 | 7 | 3 |
| 30 Sep 17 | 0 | -13 | 6 | 2 |
| 30 Jun 17 | 0 | -11 | 6 | 2 |
| 31 Mar 17 | 0 | -9 | 4 | 1 |
| 31 Dec 16 | 0 | -10 | 6 | 2 |
| 30 Sep 16 | 0 | -8 | 7 | 3 |
| 30 Jun 16 | 0 | -10 | 8 | 4 |
| 31 Mar 16 | 1 | -7 | 9 | 5 |
| 31 Dec 15 | 0 | -10 | 6 | 0 |
| 30 Sep 15 | 0 | -20 | 7 | 4 |
Quality Earnings: 6XC1 is currently unprofitable.
Growing Profit Margin: 6XC1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6XC1 is unprofitable, and losses have increased over the past 5 years at a rate of 19.4% per year.
Accelerating Growth: Unable to compare 6XC1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6XC1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 6XC1 has a negative Return on Equity (-115.31%), as it is currently unprofitable.